Under construction – not a live service
Sign in

NCT06123858Terminated

Non-alcoholic Steatohepatitis Registry Platform Study

Source: ClinicalTrials.gov · Last updated 29 Jul 2026

Reason given: Following a reassessment of the company's pipeline priorities, the sponsor has elected to discontinue this project prior to its planned completion

Brief summary (registry, in English)

This is a multi-center, prospective, observational registry platform study aimed at describing the clinical characteristics and diagnosis and treatment patterns of Chinese patients with nonalcoholic steatohepatitis (NASH) with fibrosis.

Status (registry)
Terminated
Study type
Observational
Enrollment
1122 (actual)
First submitted
25 Oct 2023
Start date
22 Nov 2023
Primary completion date
17 Oct 2025
Lead sponsor
AstraZeneca
NCT number
NCT06123858

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • History of liver transplantation;
  • Patients with bleeding tendency or coagulation dysfunction (for example, bleeding tendency, such as hemophilia, suspected hemangioma or suspected hydatid infection);
  • Exclude liver diseases caused by the following causes: alcoholic steatohepatitis, drug-induced, viral or autoimmune hepatitis, primary hemochromatosis, α1-antitrypsin deficiency, hepatolenticular degeneration, hypothyroidism, inflammatory bowel disease, Cushing's syndrome, celiac disease, β lipoprotein deficiency, lipoatrophic diabetes mellitus, Mauriac syndrome, hypopituitarism, hypogonadism, polycystic ovarian syndrome;
  • Have a history of malignant tumors in the past 5 years, excluding malignant tumors that have been cured by the investigator's judgment;

Other

  • Pregnant or lactating women.

Who the study is looking for

  • (1) Subjects must be between 18 and 75 years old when signing the informed consent form, and must have the ability to sign the consent form independently; (2) NASH patients who meet one of the following conditions:
  • Liver biopsy was performed within 24 months before enrollment, and the pathological diagnosis was NASH and the fibrosis stage was F2 or above;
  • FibroScan-AST (FAST) score ≥ 0.30 within 24 months before enrollment;
  • There are any of the following evidences of fatty liver
    • Controlled attenuation parameter (CAP) > 285 dB/m within 24 months before enrollment;
    • Liver ultrasonography showed fatty liver within 24 months before enrollment;
    • Magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) examination within 24 months before enrollment showed liver fat fraction ≥ 5%; and any of the following evidence of liver fibrosis
    • <!-- -->
    • Liver stiffness measurement (LSM) ≥ 7.5kPa by vibration-controlled transient elastography (VCTE) within 24 months before enrollment;
    • The elasticity value of magnetic resonance elastography (MRE) examination within 24 months before enrollment is ≥2.93kPa;
    • If there is no liver biopsy and no liver elastography equipment is available in the research center, FIB-4>1.3 (under 65 years old) or>2 (over 65 years old) within 3 months before enrollment.

Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (16)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
-BeijingChinaUnknown status
-ChangchunChinaUnknown status
-ChengduChinaUnknown status
-FuzhouChinaUnknown status
-GuangzhouChinaUnknown status
-HangzhouChinaUnknown status
-Inner MongoliaChinaUnknown status
-NanchangChinaUnknown status
-QingdaoChinaUnknown status
-ShanghaiChinaUnknown status
-ShenyangChinaUnknown status
-TaiyuanChinaUnknown status
-TianjinChinaUnknown status
-WenzhouChinaUnknown status
-Xi'anChinaUnknown status
-ZhengzhouChinaUnknown status

Are you the coordinator? Confirm the details

This page is information, not medical advice. Discuss any trial with your doctor.